
Meglitinides (Nateglinide & Repaglinide) can feel like the “forgotten” oral diabetes drugs—but they show up on exams, in real-world medication histories, and in questions about postprandial glucose control and hypoglycemia and weight gain risk. In this lecture from This is Why, Dr. Busti will explain the meglitinides in a clear, clinically relevant way so you can recognize them quickly and use the concepts confidently in the context of Type 2 diabetes (T2DM).
You’ll learn how to:
- Meglitinides overview: where they fit in type 2 diabetes (T2DM) therapy
- Drug names you must know: repaglinide and nateglinide
- Mechanism of action: how these insulin secretagogues stimulate insulin release (the KATP channel connection)
- Onset/duration & dosing concept: why they’re considered short-acting / prandial glucose agents
- Therapeutic application: targeting postprandial hyperglycemia and when they may (or may not) be chosen
- Adverse effects & safety: hypoglycemia, weight considerations, and key patient counseling points
The goal = make medical education easy and clinically relevant.
Chapter Table of Contents
01:42 - Agents
01:58 - Indications & Uses
02:34 - Net Benefit
03:12 - Pharmacology
05:22 - Clinical Knowledge
11:33 - Summary
If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.
Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!
#meglitinides #repaglinide #nateglinide #type2diabetes #busti
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Antidiabetic Agents Lecture Tables
Antidiabetic Agents Lecture Tables